Deal Snapshot
Endo Closes USD 540m Acquisition of BioSpecifics
Thursday 03 December 2020

Dublin-based Endo International plc (NASDAQ: ENDP) has closed the acquisition of all of the outstanding shares of New York-based commercial-stage biopharmaceutical company BioSpecifics Technologies Corp. (NASDAQ: BSTC) for an enterprise value of approximately USD 540m the company said.

Under the terms of the merger agreement, Endo, through a wholly owned subsidiary, launched an all-cash tender offer to acquire 100% of the outstanding common stock of BioSpecifics for USD 88.50 per share.

Date Published: 03/12/2020